Pfizer and BioNTech’s COVID-19 vaccine 90% effective in Phase III trial

0

The first set of data from Pfizer (NY, USA) and BioNTech’s (Mainz, Germany) Phase III clinical trial for their COVID-19 vaccine candidate, BNT162b2, indicates a 90% efficacy rate.

“Today is a great day for science and humanity,” said Albert Bourla, Pfizer Chairman and CEO. “With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”

Read the full news piece on BioTechniques now

Share:

Leave A Comment